HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥Combi-TED: Results of a Multicenter, Phase II, Open-Label, Randomized Trial Evaluating OSE2101 Plus Docetaxel or OSE2101 Plus Nivolumab as Second-Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Progressing After First-Line Chemo-Immunotherapy 🎙️ @FedericoCappuz1 🔢2661RO 🎯1-Yr OS 44% (OSE2101+Docetaxel, p=0.001) and 44% (OSE2101+Nivolumab, p=0.002) vs 26% (Docetaxel Alone, NS) (n=106) ☑️NCT04884282 🔗 https://t.co/p4tFUd6fHn @OncoAlert @Larvol @myESMO @IASLC
热度 1 · 0 赞 · 0 回复 · 1 转发
会议摘要
NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上
- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)读摘要原文 →来源：HHorinouchi · x.com